NO942072L - Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks - Google Patents

Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks

Info

Publication number
NO942072L
NO942072L NO942072A NO942072A NO942072L NO 942072 L NO942072 L NO 942072L NO 942072 A NO942072 A NO 942072A NO 942072 A NO942072 A NO 942072A NO 942072 L NO942072 L NO 942072L
Authority
NO
Norway
Prior art keywords
growth factor
fibrosis
accumulation
extracellular matrix
inhibition
Prior art date
Application number
NO942072A
Other languages
English (en)
Other versions
NO942072D0 (no
Inventor
Erkki I Ruoslahti
Wayne A Border
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Publication of NO942072D0 publication Critical patent/NO942072D0/no
Publication of NO942072L publication Critical patent/NO942072L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Fremgangsmåte for å behandle eller stanse utviklingen av sykdomstil- stander kjennetegnet ved en akkumuler- ing av ekstracellulære matriksbestand- deler ved å tilføre et middel som undertrykker aktiviteten av transfor- merende vekstfaktor p (TGF-p), en peptidvekstfaktor som er anabolsk og fører til fibrose og angiogenese. Syk- domstilstander som kan behandles på denne måte omfatter de forskjellige fibrotiske sykdomstilstander som fibrotisk cancer, lungefibrose, arteriosklerose, .postmyokardinfarkt, hjertefibrose, postangioplastisk restenose, renal interstitiell fibrose, arrdannelse og diabetisk nefropati. Fremgangsmåter for behandling .av diabetes og farmasøytiske preparater som er anvendbare i slike fremgangs- måter beskrives også.
NO942072A 1991-12-04 1994-06-03 Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks NO942072L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80328591A 1991-12-04 1991-12-04
PCT/US1992/010550 WO1993010808A1 (en) 1991-12-04 1992-12-04 INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX

Publications (2)

Publication Number Publication Date
NO942072D0 NO942072D0 (no) 1994-06-03
NO942072L true NO942072L (no) 1994-08-03

Family

ID=25186123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942072A NO942072L (no) 1991-12-04 1994-06-03 Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks

Country Status (10)

Country Link
EP (1) EP0616536B1 (no)
JP (2) JP3854307B2 (no)
AT (1) ATE177644T1 (no)
AU (2) AU670770B2 (no)
CA (1) CA2124591A1 (no)
DE (1) DE69228700T2 (no)
DK (1) DK0616536T3 (no)
FI (1) FI942622A (no)
NO (1) NO942072L (no)
WO (1) WO1993010808A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
EP0735895B1 (en) * 1993-11-19 2006-01-18 The University Of Sydney A method for preventing or controlling cataract
EP0968723B1 (en) * 1994-03-29 2009-07-01 Renovo Limited Healing of wounds or fibrotic disorders using at least one agent against a growth factor
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
WO1999034823A2 (en) * 1998-01-09 1999-07-15 University Of Utah METHODS FOR PREVENTING AND TREATING FIBROTIC DISEASES RESULTING FROM ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX INDUCED BY TGFβ USING RENIN INHIBITORS
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1423133B1 (en) 2001-08-15 2009-01-14 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
EP1478354A4 (en) * 2002-01-22 2008-09-24 Genzyme Corp USE OF TGF-BETA ANTAGONISTS IN THE TREATMENT OR PREVENTION OF CHRONIC RELEASE OF TRANSPLANT
WO2004075917A1 (ja) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. 器官または組織の線維化抑制剤
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP1983345A1 (en) * 2007-04-17 2008-10-22 Roche Diagnostics GmbH Means and method for assessing the risk of a cardiac intervention in patients suffering from a stable coronary heart disease based on GDF-15
PT2835053T (pt) 2010-03-12 2016-07-14 Genzyme Corp Terapêutica combinada para o tratamento do cancro da mama
JP6339367B2 (ja) 2010-05-17 2018-06-06 ブラウン ユニバーシティ バイグリカン変異体および関連する治療薬および使用方法
KR20130131414A (ko) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 ｉＰＳ 세포와 그 제조법
US9958458B2 (en) 2010-12-27 2018-05-01 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
ES2894398T3 (es) 2011-06-03 2022-02-14 Xoma Technology Ltd Anticuerpos específicos para TGF-beta
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
PL3064222T3 (pl) 2013-10-31 2021-04-19 Kyoto Prefectural Public University Corporation Lek terapeutyczny zawierający inhibitor sygnału tgf-beta w chorobach związanych z retikulum endoplazmatycznym i śmiercią komórki w śródbłonku rogówki
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017223268A1 (en) * 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
JP7109039B2 (ja) 2016-07-07 2022-07-29 国立大学法人千葉大学 抗線維症剤およびリン酸化Ｓｍａｄ核内移行阻害剤
WO2019143219A1 (ko) * 2018-01-22 2019-07-25 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
KR102141125B1 (ko) * 2018-01-22 2020-08-05 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
FR3090320B1 (fr) * 2018-12-19 2023-03-03 Karim Bouzakri Utilisation de la decorine dans le traitement du diabete
US12048731B2 (en) * 2019-04-11 2024-07-30 Daegu Gyeongbuk Institute Of Science And Technology Appetite suppression with pharmaceutical compositions containing biglycan as an active ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654938B2 (en) * 1989-09-29 1994-12-01 La Jolla Cancer Research Foundation Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors

Also Published As

Publication number Publication date
AU3242993A (en) 1993-06-28
EP0616536A1 (en) 1994-09-28
CA2124591A1 (en) 1993-06-10
AU670770B2 (en) 1996-08-01
WO1993010808A1 (en) 1993-06-10
DK0616536T3 (da) 1999-10-11
JP2004043507A (ja) 2004-02-12
AU7051896A (en) 1997-01-16
FI942622A0 (fi) 1994-06-03
JP3854307B2 (ja) 2006-12-06
EP0616536B1 (en) 1999-03-17
ATE177644T1 (de) 1999-04-15
DE69228700D1 (de) 1999-04-22
JPH07504650A (ja) 1995-05-25
NO942072D0 (no) 1994-06-03
DE69228700T2 (de) 1999-09-09
FI942622A (fi) 1994-07-27

Similar Documents

Publication Publication Date Title
NO942072L (no) Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks
El-sherif et al. Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations
Remuzzi et al. Haemolytic-uraemic syndrome: deficiency of plasma factor (s) regulating prostacyclin activity?
ATE193541T1 (de) Insulinotropes hormon
JPS6429308A (en) Treatment of hyperhydrosis, psoriasis and wrinkle
NO921119D0 (no) Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks
EP1123129A4 (en) SYSTEMS AND COMPOUNDS FOR ADMINISTRATION OF MEDICINE IN INTERSTITIAL REGIONS OF MYOCARD
EA199900861A1 (ru) Усеченные белки, родственные фактору роста эндотелия сосудов
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
RU2738416C2 (ru) Длительно действующее производное адреномедуллина
CY1110445T1 (el) Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια
DE69228749T2 (de) Neuartige polypeptide und ihre verwendung
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
WO2000078776A3 (en) Thiophene a2a receptor agonists
Louis et al. A diabetogenic polypeptide from bovine adenohypophysis similar to that excreted in lipoatrophic diabetes
WO2022030580A1 (ja) 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途
EA200400428A1 (ru) Применение лютеинизирующего гормона при контролируемой гиперстимуляции яичников
Kaltenbach et al. Treatment of hypertrophic cardiomyopathy: Relation to pathological mechanisms
Le Coniat et al. (956) Chronic in Vivo Animal Data on a Wireless Systolic Synchronized Mini-Cardiac Pump
WO2000047235A3 (en) Methods of stimulating angiogenesis
White Hormones of the Adenohypophysis
WO2020218228A1 (ja) カテーテルアブレーション手術後の不整脈を予防又は治療するための医薬
DE2149470C3 (de) Prednisonderivat, Verfahren zu seiner Herstellung und dieses enthaltendes Mittel
CN108358827A (zh) 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
Lutay et al. Addition of ivabradine during beta-blockers titration improves systolic and diastolic LV function in patients with recent Q-wave myocardial infarction